Tyrosine kinase inhibitors have revolutionized the treatment of metastatic renal cell carcinoma (RCC).
Drugs such as sorafenib, sunitinib and pazopanib act on the VEGF receptor pathway, but they can also inhibit other kinases, resulting in off-target toxicities. Tivozanib was developed due to its potency and selectivity against VEGF receptors 1-3. It has a favorable pharmacokinetic profile after oral administration and a long plasma half-life. In the Phase III TIVO-1 trial, it demonstrated a higher response rate and longer progression-free survival than sorafenib with a better side-effect profile. It is currently awaiting approval to be used in the first-line treatment of metastatic RCC. An early-phase trial has also shown its tolerability at full dose when given with the mTOR inhibitor temsirolimus, suggesting its potential in combination treatment. This article examines tivozanib from its laboratory to clinical development, as well as its relevance and future role in the treatment of RCC in the era of the tyrosine kinase inhibitors.
Written by:
Wong HH, Eisen T. Are you the author?
Cambridge University Health Partners, Addenbrooke's Hospital, Cambridge, UK.
Reference: Expert Rev Anticancer Ther. 2013 Jun;13(6):649-60.
doi: 10.1586/era.13.40
PubMed Abstract
PMID: 23773100
UroToday.com Renal Cancer Section
